Fig. 5

The associations of TICS with the efficacy of ADT and immunotherapy. A Kaplan–Meier analysis of the BCRFS of ADT patients (GSE111177) grouping with PSA level, Gleason score, or the TICS. B ROC curve for predicting patient response to immunotherapy based on the TICS. C Kaplan–Meier analysis of the BCRFS/rPFS/OS of the high- and low-TICS patients with immunotherapy. D The immune cell composition of the high- and low-TICS patients with immunotherapy. E Correlation of the immune cell fraction and the TICS of patients with immunotherapy. (ADT androgen deprivation therapy, PSA prostate specific antigen, HR hazard ratio, BCR biochemical recurrence, CI confidence interval, AUC area under the curve, rPFS radiographic progression-free survival.)